Related Experiment Video
Updated: May 16, 2026

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
Management of spasticity from spinal cord dysfunction
1Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, USA. strommen.jeffrey@mayo.edu
Abstract:
Spasticity is a common component of those with spinal cord dysfunction. Spasticity can lead not only to pain and potential secondary complications such as contracture and pressure sores but also to significant functional impairment. The clinician must identify specific goals of spasticity treatment and assess the potential benefit of spasticity, particularly as it pertains to transfers and ambulation. Conservative treatment measures that include avoidance and identification of potential noxious stimuli and a daily stretching program that can be performed by the patient or caregivers are initiated in all patients.
Related Concept Videos
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Spinal Cord Injury ll: Pathophysiology
Alterations in Muscle Tone ll
Skeletal Muscle Relaxants: Therapeutic Uses
Secondary Spinal Cord Injury llI: Pathophysiology
